{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 145,
  "pageCount": 239,
  "prevPage": 144,
  "nextPage": 146,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses expert quotes to frame the company's strategic pivot as a sign of desperation and loss of identity.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/145",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-145",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The Omnia launch admits that all of Nevro’s previous clinical data is “hogwash.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b343-003a0318855d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.06,
        "y": 0.37
      },
      "kind": "list",
      "text": "A former Nevro sales executives stated that Omnia erases Nevro’s identity, and that Medtronic and Boston Scientific already tried and failed with the same all-things-to-all-people product strategy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aa2c9e6-3516-44cd-a6f0-696e0efeac93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.06,
        "y": 0.19
      },
      "kind": "list",
      "text": "The Omnia launch admits that all of Nevro’s previous clinical data is “hogwash.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6084900c-6c58-4e07-a838-f6d4e844136a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Omnia erodes Nevro’s credibility and muddles the company’s message (cont'd)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4739da2f-3973-4cf5-9582-700feb5a38d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.1,
        "y": 0.65
      },
      "kind": "quote",
      "text": "“The Omnia launch was an acknowledgement that they needed to change course because the novelty and newness of high frequency has worn off.” – Former regional sales manager in charge of one of Nevro’s largest territories",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55f3417c-2eda-40ac-bb20-fd6380bea4d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.1,
        "y": 0.44
      },
      "kind": "quote",
      "text": "“Omnia is not going to do it for Nevro. The issue is that they’ve now lost their identity. They’re now the same as everyone else... Omnia is not differentiated... Medtronic and Boston Scientific already went to market saying we can do other waveforms and things and it hasn’t worked for them.” – Former sales executive now at a key competitor",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57152d05-5a82-4326-9812-8fff100f6e71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.1,
        "y": 0.24
      },
      "kind": "quote",
      "text": "“All of their clinical data that they first gained market share with - they have now said through their actions of launching Omnia that it was all hogwash, because they now offer a product that does lower frequency.” – Longtime C-level executive in the SCS space",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfd3a7c2-5dad-4ad3-8440-03a9c25da084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.1,
        "y": 0.78
      },
      "kind": "quote",
      "text": "“Nevro has lost their identity. Going toward they’re positioning around Omnia which can do everything. They’re no longer differentiated which creates a big problem. Being different is one of the key things in the SCS market.” – Former sales executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdf073a4-7a97-4ba3-bffd-fbaffafe0245",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“All of their clinical data that they first gained market share with - they have now said through their actions of launching Omnia that it was all hogwash, because they now offer a product that does lower frequency.” — Longtime C-level executive in the SCS space; “Omnia is not going to do it for Nevro. The issue is that they’ve now lost their identity. They’re now the same as everyone else. The only product in the space that’s differentiated is the Abbot IPG. Nevro, Boston Scientific, others are all saying exactly the same thing. They’re all saying burst, different, waveforms, etc. Omnia is not differentiated. It has nothing specific that will hit the nail on the head for doctors. Omnia’s burst waveform isn’t actually a burst. They’re claiming it’s something it’s not. I just don’t see it being an effective strategy. Medtronic and Boston Scientific already went to market saying we can do other waveforms and things and it hasn’t worked for them.” — Former sales executive now at a key competitor; “The Omnia launch was an acknowledgement that they needed to change course because the novelty and newness of high frequency has worn off.” — Former regional sales manager in charge of one of Nevro’s largest territories; “Nevro has lost their identity. Going toward they’re positioning around Omnia which can do everything. They’re no longer differentiated which creates a big problem. Being different is one of the key things in the SCS market.” — Former sales executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b343-07d63b579efc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4ddfe99-5a0d-4dfd-b791-f81d93a1784a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "10. The new Omnia stimulator, the centerpiece of Nevro’s turnaround hopes, is a Hail Mary and colossal flop",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9c9be97-dec7-4949-a4fd-cedd3498fe66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3f57d74-0410-4055-b10f-ca3e56747316",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}